Chimerix Inc (CMRX) Receives Average Recommendation of “Hold” from Brokerages

Chimerix Inc (NASDAQ:CMRX) has been assigned a consensus rating of “Hold” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and one has given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $7.67.

Several analysts have recently commented on the stock. ValuEngine lowered shares of Chimerix from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research report on Friday, November 10th. HC Wainwright assumed coverage on shares of Chimerix in a research report on Friday, February 2nd. They set a “buy” rating and a $10.00 price target on the stock. Finally, JPMorgan Chase & Co. lowered shares of Chimerix from a “neutral” rating to an “underweight” rating in a research report on Wednesday.

In other news, insider Linda M. Richardson sold 19,833 shares of Chimerix stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $4.47, for a total transaction of $88,653.51. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.40% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of CMRX. Bank of New York Mellon Corp increased its holdings in Chimerix by 3.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 253,367 shares of the biopharmaceutical company’s stock valued at $1,381,000 after purchasing an additional 8,287 shares during the last quarter. Alliancebernstein L.P. increased its holdings in Chimerix by 8.3% in the 2nd quarter. Alliancebernstein L.P. now owns 70,200 shares of the biopharmaceutical company’s stock valued at $383,000 after purchasing an additional 5,400 shares during the last quarter. Teachers Advisors LLC increased its holdings in Chimerix by 53.5% in the 2nd quarter. Teachers Advisors LLC now owns 107,179 shares of the biopharmaceutical company’s stock valued at $584,000 after purchasing an additional 37,361 shares during the last quarter. Northern Trust Corp increased its holdings in Chimerix by 10.4% in the 2nd quarter. Northern Trust Corp now owns 696,440 shares of the biopharmaceutical company’s stock valued at $3,795,000 after purchasing an additional 65,335 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Chimerix by 38.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,448,250 shares of the biopharmaceutical company’s stock valued at $7,893,000 after purchasing an additional 404,914 shares during the last quarter. Hedge funds and other institutional investors own 70.33% of the company’s stock.

Chimerix (CMRX) opened at $4.93 on Wednesday. Chimerix has a 12 month low of $4.17 and a 12 month high of $6.64. The firm has a market cap of $229.98, a P/E ratio of -3.45 and a beta of 1.42.

WARNING: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/14/chimerix-inc-cmrx-receives-average-recommendation-of-hold-from-brokerages.html.

Chimerix Company Profile

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply